Voyager Therapeutics annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Voyager Therapeutics Revenue Growth & History (VYGR)
Voyager Therapeutics reported $40.4M in revenue for fiscal 2025, a decrease of 49.53% from the previous fiscal year.
View full Voyager Therapeutics company overviewVoyager Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $40.4M | −$39.6M | −49.53% |
| 2024 | 2024-12-31 | $80.0M | −$170.0M | −68.00% |
| 2023 | 2023-12-31 | $250.0M | $209.1M | +511.16% |
| 2022 | 2022-12-31 | $40.9M | $3.5M | +9.33% |
| 2021 | 2021-12-31 | $37.4M | −$133.7M | −78.14% |
| 2020 | 2020-12-31 | $171.1M | $66.7M | +63.93% |
| 2019 | 2019-12-31 | $104.4M | $96.8M | +1270.14% |
| 2018 | 2018-12-31 | $7.6M | −$2.5M | −24.82% |
| 2017 | 2017-12-31 | $10.1M | −$4.1M | −28.73% |
| 2016 | 2016-12-31 | $14.2M | −$3.1M | −17.96% |
| 2015 | 2015-12-31 | $17.3M | — | — |
Voyager Therapeutics quarterly revenue
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.2M | −$2.0M | −39.13% |
| Q1 2026 | 2026-03-31 | $2.6M | −$3.9M | −59.94% |
| Q4 2025 | 2025-12-31 | $15.3M | $9.1M | +144.28% |
| Q3 2025 | 2025-09-30 | $13.4M | −$11.3M | −45.73% |
| Q2 2025 | 2025-06-30 | $5.2M | −$24.4M | −82.42% |
| Q1 2025 | 2025-03-31 | $6.5M | −$13.0M | −66.83% |
| Q4 2024 | 2024-12-31 | $6.3M | −$83.8M | −93.03% |
| Q3 2024 | 2024-09-30 | $24.6M | $20.0M | +433.79% |
| Q2 2024 | 2024-06-30 | $29.6M | $24.7M | +509.48% |
| Q1 2024 | 2024-03-31 | $19.5M | −$131.0M | −87.03% |
| Q4 2023 | 2023-12-31 | $90.1M | $91.6M | +5914.14% |
| Q3 2023 | 2023-09-30 | $4.6M | −$36.5M | −88.77% |
| Q2 2023 | 2023-06-30 | $4.9M | $4.1M | +581.60% |
| Q1 2023 | 2023-03-31 | $150.5M | $149.8M | +22769.30% |
| Q4 2022 | 2022-12-31 | −$1.5M | −$29.6M | −105.52% |
| Q3 2022 | 2022-09-30 | $41.1M | $39.6M | +2672.33% |
| Q2 2022 | 2022-06-30 | $712,000 | −$645,000 | −47.53% |
| Q1 2022 | 2022-03-31 | $658,000 | −$5.8M | −89.88% |
| Q4 2021 | 2021-12-31 | $28.1M | $21.5M | +329.48% |
| Q3 2021 | 2021-09-30 | $1.5M | −$116.4M | −98.74% |
| Q2 2021 | 2021-06-30 | $1.4M | −$27.3M | −95.27% |
| Q1 2021 | 2021-03-31 | $6.5M | −$11.6M | −64.02% |
| Q4 2020 | 2020-12-31 | $6.5M | −$26.1M | −79.99% |
| Q3 2020 | 2020-09-30 | $117.8M | $97.4M | +476.73% |
| Q2 2020 | 2020-06-30 | $28.7M | −$17.4M | −37.77% |
| Q1 2020 | 2020-03-31 | $18.1M | $12.9M | +247.64% |
| Q4 2019 | 2019-12-31 | $32.7M | $30.7M | +1527.19% |
| Q3 2019 | 2019-09-30 | $20.4M | $18.3M | +875.79% |
| Q2 2019 | 2019-06-30 | $46.1M | $43.5M | +1689.79% |
| Q1 2019 | 2019-03-31 | $5.2M | $4.3M | +451.70% |
| Q4 2018 | 2018-12-31 | $2.0M | −$4.3M | −68.36% |
| Q3 2018 | 2018-09-30 | $2.1M | $946,000 | +82.40% |
| Q2 2018 | 2018-06-30 | $2.6M | $1.4M | +118.78% |
| Q1 2018 | 2018-03-31 | $942,000 | −$522,000 | −35.66% |
| Q4 2017 | 2017-12-31 | $6.3M | $4.0M | +168.67% |
| Q3 2017 | 2017-09-30 | $1.1M | −$2.2M | −65.30% |
| Q2 2017 | 2017-06-30 | $1.2M | −$2.5M | −68.36% |
| Q1 2017 | 2017-03-31 | $1.5M | −$3.4M | −69.69% |
| Q4 2016 | 2016-12-31 | $2.4M | −$2.6M | −52.16% |
| Q3 2016 | 2016-09-30 | $3.3M | −$1.6M | −33.00% |
| Q2 2016 | 2016-06-30 | $3.7M | −$1.2M | −23.83% |
| Q1 2016 | 2016-03-31 | $4.8M | $2.3M | +87.50% |
| Q4 2015 | 2015-12-31 | $4.9M | — | — |
| Q3 2015 | 2015-09-30 | $4.9M | — | — |
| Q2 2015 | 2015-06-30 | $4.9M | — | — |
| Q1 2015 | 2015-03-31 | $2.6M | — | — |
Voyager Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue declined from $171.1M to $40.4M, a compound annual decline of 25.09%. Voyager Therapeutics's latest reported quarter, Q2 2026, generated $3.2M in revenue, a decrease of 39.13% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Voyager Therapeutics source filings ↗